In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Immutep Ltd (PRRUF – Research Report), with a price target of A$0.65. The company’s shares closed last Thursday at $0.24.
According to TipRanks, Wakim is ranked #6966 out of 8753 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immutep Ltd with a $0.58 average price target.
The company has a one-year high of $0.30 and a one-year low of $0.13. Currently, Immutep Ltd has an average volume of 2,510.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immutep Ltd (PRRUF) Company Description:
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Read More on PRRUF:
